Blab AI
Insilico Medicine and SK Biopharmaceuticals Announce $2.5 B Neuroimmune Drug Discovery Partnership
At the BIO 2026 International Convention in Cambridge, Mass., Insilico Medicine and SK Biopharmaceuticals unveiled a research‑and‑development alliance that could be worth more than $2.5 billion. The collaboration will harness AI‑enabled technology to uncover new drug candidates for neuroimmune disorders of the central nervous system (CNS), with Insilico receiving up to $18 million in upfront and milestone payments.
Neuroimmune disorders—including neuroinflammatory, neurodegenerative and rare neurological conditions—have long suffered from low clinical success rates and a pressing unmet need. Under the agreement, Insilico will deploy its proprietary Pharma.AI platform, which spans target validation, generative chemistry and molecule optimisation, to spot and refine novel candidates. SK will bring its extensive development and clinical expertise to steer late‑stage progress and eventual commercialization.
SK’s President and CEO, Donghoon Lee, described the partnership as a “critical milestone in expanding our growth beyond epilepsy into new CNS therapeutic areas,” citing the company’s success with Cenobamate. SK Life Science, Inc., the U.S. arm of SK, will oversee regulatory and commercial activities in the United States, while the partnership will tap SK’s global reach.
Insilico, a clinical‑stage generative AI‑driven drug discovery firm listed on the Hong Kong Stock Exchange (3696.HK), has accelerated pre‑clinical candidate nomination: 31 candidates since 2021, 13 of which have achieved IND approval or clearance. The company claims its AI‑automation platform can bring a candidate to nomination in 12‑18 months—half the industry average of 2.5‑4 years. The deal’s financial structure, with up to $18 million in upfront and near‑term milestone payments, marks a record for Insilico with Asia‑Pacific partners.
The total potential value of the deal includes development, regulatory and commercial milestone payments, as well as single‑digit royalties on net sales after commercialization. The partnership also underscores Insilico’s broader strategy of extending Pharma.AI beyond small molecules to advanced modalities and other sectors such as advanced materials, agriculture and veterinary medicine. Insilico’s MMAI Gym, a training and benchmarking environment for scientific AI, has already attracted partners like Human Longevity and Liquid AI.
SK Biopharmaceuticals, known for bringing the first Korean‑developed drug—XCOPRI (cenobamate)—to the U.S. market, has invested in next‑generation growth drivers, including radiopharmaceutical therapies and targeted protein degradation. The company integrates AI and digital technologies across the drug discovery, development and treatment continuum to build a patient‑centred ecosystem.
The collaboration, announced at BIO 2026, highlights the expanding role of AI in drug discovery and the willingness of established biopharma to partner with AI‑native companies to accelerate therapeutic development. While the partnership’s long‑term clinical outcomes remain to be seen, the announced terms and the record financial commitment signal a significant shift toward AI‑driven discovery pipelines in the neuroimmune space.
Neuroimmune disorders—including neuroinflammatory, neurodegenerative and rare neurological conditions—have long suffered from low clinical success rates and a pressing unmet need. Under the agreement, Insilico will deploy its proprietary Pharma.AI platform, which spans target validation, generative chemistry and molecule optimisation, to spot and refine novel candidates. SK will bring its extensive development and clinical expertise to steer late‑stage progress and eventual commercialization.
SK’s President and CEO, Donghoon Lee, described the partnership as a “critical milestone in expanding our growth beyond epilepsy into new CNS therapeutic areas,” citing the company’s success with Cenobamate. SK Life Science, Inc., the U.S. arm of SK, will oversee regulatory and commercial activities in the United States, while the partnership will tap SK’s global reach.
Insilico, a clinical‑stage generative AI‑driven drug discovery firm listed on the Hong Kong Stock Exchange (3696.HK), has accelerated pre‑clinical candidate nomination: 31 candidates since 2021, 13 of which have achieved IND approval or clearance. The company claims its AI‑automation platform can bring a candidate to nomination in 12‑18 months—half the industry average of 2.5‑4 years. The deal’s financial structure, with up to $18 million in upfront and near‑term milestone payments, marks a record for Insilico with Asia‑Pacific partners.
The total potential value of the deal includes development, regulatory and commercial milestone payments, as well as single‑digit royalties on net sales after commercialization. The partnership also underscores Insilico’s broader strategy of extending Pharma.AI beyond small molecules to advanced modalities and other sectors such as advanced materials, agriculture and veterinary medicine. Insilico’s MMAI Gym, a training and benchmarking environment for scientific AI, has already attracted partners like Human Longevity and Liquid AI.
SK Biopharmaceuticals, known for bringing the first Korean‑developed drug—XCOPRI (cenobamate)—to the U.S. market, has invested in next‑generation growth drivers, including radiopharmaceutical therapies and targeted protein degradation. The company integrates AI and digital technologies across the drug discovery, development and treatment continuum to build a patient‑centred ecosystem.
The collaboration, announced at BIO 2026, highlights the expanding role of AI in drug discovery and the willingness of established biopharma to partner with AI‑native companies to accelerate therapeutic development. While the partnership’s long‑term clinical outcomes remain to be seen, the announced terms and the record financial commitment signal a significant shift toward AI‑driven discovery pipelines in the neuroimmune space.
